Skip to main content
HANALL BIOPHARMA CO.,LTD logo

HANALL BIOPHARMA CO.,LTD — Investor Relations & Filings

Ticker · 009420 ISIN · KR7009420001 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2024-11-06 Transaction in Own Shar…
Country KR South Korea
Listing KO 009420

About HANALL BIOPHARMA CO.,LTD

http://www.hanallbiopharma.com/

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.

Recent filings

Filing Released Lang Actions
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '자기주식처분결과보고서' (Report on the Results of Disposal of Treasury Shares) filed with the Financial Supervisory Service (FSS) in South Korea. It details the specific number of shares disposed of (55,331 shares), the purpose (stock option exercise), and the resulting change in treasury share holdings. This falls under the category of a company reporting the disposal or transaction of its own shares.
2024-11-06 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for HanAll Biopharma for the 3rd quarter of 2024. It provides key financial highlights such as revenue, operating profit, and net income, and explicitly states that these are provisional figures subject to change after external audit. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results. Q3 2024
2024-10-30 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a formal regulatory filing titled '주요사항보고서(자기주식 처분 결정)' which translates to 'Report on Major Matters (Decision on Disposal of Treasury Shares)'. It details the company's decision to dispose of treasury shares due to employee stock option exercises. This falls under the category of a company reporting the sale or transfer of its own shares, which is classified as 'Transaction in Own Shares' (POS).
2024-10-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by the National Pension Service regarding their holdings in HanAll Biopharma. This type of filing is a standard regulatory disclosure for major shareholders (insiders/institutional investors) to report changes in their equity positions, which falls under the category of Major Shareholding Notification.
2024-10-08 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed by the National Pension Service (NPS) regarding their stake in HanAll Biopharma. This is a standard regulatory filing in South Korea (DART system) used to disclose changes in significant share ownership (crossing thresholds). Based on the provided definitions, this falls under 'Major Shareholding Notification'.
2024-10-07 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for HanAll Biopharma Co., Ltd., covering the period from January 1, 2024, to June 30, 2024. It contains comprehensive financial statements, management discussion and analysis, and operational details, which aligns with the definition of an Interim/Quarterly Report (IR). It is not a mere announcement or certification, as it provides substantive financial data and business analysis. H1 2024
2024-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.